UK issues AI-in-medicine regulatory recommendations; FDA pauses new enrollment in Biohaven epilepsy trials

The United Kingdom has released a set of recommendations aimed at governing the use of artificial intelligence in medical applications. The guidance outlines how AI tools should be evaluated and monitored to ensure safety and efficacy in patient care.

In the United States, the Food and Drug Administration has stopped new patient enrollment in Biohaven's ongoing epilepsy clinical trials. The agency has not provided further details on the reasons for the pause.

These regulatory moves highlight growing scrutiny of emerging technologies and trial conduct, signaling that companies will need to align closely with evolving oversight in both AI deployment and clinical development.